MedTrace Logo

Mechanisms of Hypertension in Women With Polycystic Ovary Syndrome

NCT04327934 · Status: TERMINATED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2024-02-02

Study results available
· View outcomes & findings →

Summary

Women with androgen excess polycystic ovary syndrome (AE-PCOS) leads to hypertension.

Conditions

Interventions

DRUG

GnRH antagonist

GnRH antagonist up to 16 days.

DRUG

GnRH antagonist + MethylTESTOSTERone 5 MG

GnRH antagonist + MethylTESTOSTERone 5 MG up to 5 days.

Sponsors & Collaborators

  • Yale University

    lead OTHER

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH

Principal Investigators

  • Nina Stachenfeld, PhD · Yale University

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-12-01
Primary Completion
2022-06-30
Completion
2022-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04327934 on ClinicalTrials.gov